Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,338 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Activity scheduling Clear all
Completed Phase 3 Interventional Results available

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

NCT03875729
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
teplizumab, Placebo
Biological
Lead sponsor
Provention Bio, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional

Brain Injury Education and Outpatient Navigation-1stBIEN

NCT05261477
View directory record Official record
Conditions
Brain Injuries, Traumatic, Rehabilitation
Interventions
Bilingual Brain Injury Education and outpatient Navigation for Hispanic families
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
3 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Colorado Springs, Colorado • Portland, Oregon • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01376297
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
11
States / cities
Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Remote Monitoring for Equity in Advancing Control of Hypertension

NCT05481892
View directory record Official record
Conditions
Hypertension
Interventions
Cellular Home blood pressure (BP) monitoring
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892
View directory record Official record
Conditions
Panic Disorder
Interventions
quetiapine XR, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 25, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

NCT02588092
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
ADCT-301
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
11
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 25, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

NCT06560632
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Francisco, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

Building Infrastructure for Community Capacity in Accelerating Integrated Care

NCT04092777
View directory record Official record
Conditions
Mental Health
Interventions
Strong Minds, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Quincy, Massachusetts • Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Program to Increase Physical Activity Among Blacks

NCT00991731
View directory record Official record
Conditions
Physical Activity
Interventions
Faith-based, Non-faith-based
Behavioral
Lead sponsor
Melicia Whitt-Glover
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions

NCT06596902
View directory record Official record
Conditions
Obesity Prevention, Heart Disease
Interventions
Physical Activity
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
6 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

Vitamin D and Type 2 Diabetes - Treat-To-Target

NCT07448974
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes (T2DM)
Interventions
Vitamin D (Cholecalciferol ), Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease

NCT03029468
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
cognitive behavioral therapy, eEducation
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 25, 2026, 2:58 AM EDT
Not yet recruiting Not applicable Interventional

The Effect of Vagus Nerve Stimulation on Pain and Functional Activities in Individuals With Chronic Widespread Pain

NCT07080749
View directory record Official record
Conditions
Widspread Chronic Pain, Fibromyalgia
Interventions
Vagal nerve stimulation through deep exhalation exercise, Vagal nerve stimulation through ear electrical stimulation, No intervention (observational study)
Other
Lead sponsor
University of North Georgia
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dahlonega, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

NCT01550224
View directory record Official record
Conditions
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Interventions
Temozolomide, Vorinostat
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

NCT05364450
View directory record Official record
Conditions
Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasms, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Human, Anxiety, Fear
Interventions
Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 25, 2026, 2:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)

NCT07226440
View directory record Official record
Conditions
Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 2:58 AM EDT
Active, not recruiting Not applicable Interventional

ResIlience-based Stigma REdUction Program ("Rise-up")

NCT05174936
View directory record Official record
Conditions
HIV/AIDS, Stigma, Social, Emotional Adjustment
Interventions
PLWH intervention, Family member intervention, Healthcare provider intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial

NCT03916484
View directory record Official record
Conditions
Hiv, HIV/AIDS, Medication Adherence, Sexual Behavior, Sexually Transmitted Infections (Not HIV or Hepatitis)
Interventions
AllyQuest HIV Medication Adherence app-delivered intervention, AllyQuest HIV Medication Adherence app-delivered intervention + NSC
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Detroit, Michigan • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 25, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

NCT03207815
View directory record Official record
Conditions
Noninfectious Uveitis
Interventions
Filgotinib, Placebo to match filgotinib, Prednisone
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Palo Alto, California • Golden, Colorado • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Pre-Habilitation Exercise Intervention

NCT02849717
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colon Cancer, Rectal Cancer, Diverticular Disease
Interventions
Exercise for Cancer Patients
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 25, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

NCT01041235
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions
ATI-1123 (active drug = docetaxel)
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 25, 2026, 2:58 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

NCT05388435
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SKL27969
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 25, 2026, 2:58 AM EDT